Study: Access to Targeted Lung Cancer Drug Is Cost-Prohibitive Globally
A new study that examined the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer, could help guide drug-pricing strategies to reduce financial burdens and increase the number of patients who benefit from treatment.
30-May-2024 2:05 PM EDT
Add to Favorites